Press Photos

Through its 2018 acquisition of SynCo Bio Partners B.V. in Amsterdam, the Netherlands, Wacker Chemie AG strengthened its pharmaceutical protein business and expanded its portfolio – an important step to keep pace with the rapidly growing biologics market. As a result, Wacker Biotech now has three sites: Jena, Halle and Amsterdam, with a total of about 330 employees. (Photo: Wacker Chemie AG)

Specialists in the field of microbial production: Wacker Biotech GmbH is a full-service contract manufacturer of biologics with more than 20 years of experience with microbial systems. The company’s core competencies include the manufacture of active pharmaceutical ingredients, vaccines and live bacteria. (Photo: Wacker Chemie AG)

Production at Wacker Biotech GmbH: the Munich-based WACKER Group entered the field of contract manufacturing for pharmaceutical proteins when it acquired Prothera GmbH and subsequently renamed it Wacker Biotech in 2005. (Photo: Wacker Chemie AG)

WACKER is the world’s first manufacturer capable of using renewable resources to produce commercial quantities not only of dispersions based on vinyl acetate-ethylene copolymer (VAE), but also of further products based on vinyl acetate. To do so, the company uses a certified biomass balanced method for acetic acid, generated as a byproduct in the woodworking industry.

The anti-graffiti agent has the consistency of honey and is diluted with a solvent before application. The active-ingredient content, viscosity and color can be adjusted. The anti-graffiti coating can be applied by brush, roller or spray.